HCV-2 - aphc.info

advertisement
PARIS HEPATITIS CONFERENCE 2012
30-31 January 2012
What’s new in HCV genotype 2?
Alessandra Mangia
S.Giovanni Rotondo,ITALY
Key issues
•
•
•
•
Epidemiological background
Response rates with Peg/RBV
Does IL28B plays any role?
New therapeutic approaches
HCV genotype 2 prevalence in Europe and Canada
Mean rate
8.2%
9%
27%
M.Conrberg et al 2010
HCV 2 and tx in Italy
HCV genotype distribution in 1604 pts
enrolled into the Prophesys study in Italy
7%
27%
62%
HCV-4
(n=70)
HCV-3
(n=275
HCV-2
(n=478)
HCV-1
(n=777)
4.3%
17%
30%
48%
Prophesys 2 Final analysis
5%
G1
G2
G3
G4
Peg-IFN-a + ribavirin:
incidence of treatment failure
Peg-IFN-a 2a
+ ribavirin1
58%
54%
48%
Peg-IFN-a 2a
+ ribavirin2
24%
Peg-IFN-a 2b
+ ribavirin3
16%
Genotype 1
Peg-IFN: peginterferon
18%
Genotypes 2/3
1. Fried MW, et al. N Engl J Med 2002;347:975–982
2. Hadziyannis S, et al. Ann Intern Med 2004;40:346–355
3. Manns M, et al. Lancet 2001;358:958–965
Demographic characteristics of Italian
pts with HCV 2/3 evaluated in the
interim analysis of the WRITE study
HCV 3
(n=303)
HCV 2
(n=200)
P value
Mean age
(years)
44.2
56.5
0.001
Male gender
71%
46%
0.001
20.5%
10.5%
0.003
Blood transfusion
13%
6%
0.0001
Previous surgery
16%
33%
Unknown
22%
48%
IVDA
56%
6%
Fibrosis stage 4
WRITE STUDY Data on file
Final results from 7163 naive, pts
enrolled in the PROPHESYS study
 To investigate the predictive value of virological
responses by week 2, 4 and 12 on SVR.
 Patients infected with HCV genotype 2 had the highest
rates of on-treatment virological responses and SVR
rates among all groups (71% vs 42% in genotype 1)
 The highest relapse rates occurred among genotype 1
patients and the lowest relapse rates in genotype 2
patients (27% vs 11% in genotype 1)
Marcellin p et al AASLD 2011
PROPHESYS STUDY: Virological response
over time in HCV 2 and 3 patients
On Treatment, EOT and SVR Response
HCV 3
94
100%
92
84
91
88
74
80%
71
61
60%
40%
20%
0%
wk4
wk 12
EOT
SVR
Marcellin P et al AASLD 2011
SVR rates by RVR in HCV-2 pts enrolled in
studies on short or standard tx duration
No of pts
RVR
(%)
SVR in 12/16
weeks (%)
Relapse
(%)
SVR in 24
weeks (%)
Relapse
(%)
150
86
94 (45/50)
6 (3/50)
95 (95/100)
3 (3/100)
455/728
69
81 (196/243)
17 (39/233)
92 (194/212)
5 (10/204)
vonWagner
39
97
95 (18/19)
0.5 (1/19)
95 (18/19)
0.5 (1/19)
Mecenate
116
68
80 (32/40)
3 (1/34)
79 (31/39)
0
Dalgard
85
71
93 (27/29)
7 (2/29)
97 (30/31)
3 (1/31)
Mangia
213
64
87 (89/102)
3 (3/98)
76 (40/53)
3 (1/32)
Yu
Shiffman
Diago,
SVR rates by RVR in HCV-3 pts enrolled in
studies on short or standard tx duration
No of pts
RVR
(%)
SVR in 12/16
weeks (%)
Relapse
(%)
SVR in 24
weeks (%)
Relapse
(%)
408/728
56
84 (236/215)
14 (29/206)
90 (173/193)
7 (13/180)
vonWagner
113
91
76 (39/51)
16(8/52)
75 (39/52)
4 (2/51)
Mecenate
94
68
87 (28/32)
3 (1/29)
69 (22/32)
8 (2/24)
Dalgard
119
70
84 (93/110)
15 (17/110)
92 (106/115)
8 (9/115)
Mangia
70
59
77 (24/31)
14 (4/928)
100 (10/10)
0
Shiffman
Diago,
Rates of non RVR and SVR in pts with HCV2 and HCV-3 who received 24 wks of tx
No of
HCV-2 pts
Non RVR
(%)
SVR after
24 wks in
non
RVR
No of
HCV-3 pts
Non RVR
(%)
SVR after
24 wks in
non
RVR
Yu
150
14
77 (10/13)
NA
NA
NA
Shiffman
728
43
53 (58/109)
727
13
39 (58/150)
Mangia
213
35
78 (45/58)
70
41
41 (9/22)
Mecenate
116
32
60 (22/37)
94
32
60 (18/30)
Dalgard
85
29
75 (15/20)
343
31
56 (54/96)
SNP near IL28B predicts SVR with PR
p = 2.06 x 10–3
p = 4.39 x 10–3
p = 1.37 x 10–28
TT TC CC
TT TC CC
TT TC CC
African
American
Hispanic
SVR (%)
p = 1.06 x 10–25
rs 129760 predicts SVR
TT TC CC
n=102 n=433 n=336
-chromosome 19
-3kb upstream of IL28B
-P=1.37 x10-28 across
all population groups
Caucasian
n=70
n=91
n=30
n=14
n=35
n=26
n=186 n=559 n=392
Combined
SVR
Non-SVR
Ge D, et al. Nature 2009; 461: 399–401
Original study protocol
n=268*
Week 0
Standard-24 (SD)
Variable-12/24 (VD)
PegIFN + ribavirin for 24 weeks
n=68
PegIFN + RBV for 12 or 24 weeks
n=200
Week 4
HCV-RNA -ve
HCV-RNA +ve
Treated for 12 weeks
n=122
Treated for 24 weeks
n=78
Drop out
n=3
Drop out
n=2
Completed
n=120
Week 12
Drop out
n=4
Week 24
Completed
n=64
* 13 patients did not provide informed consent; genotyping failed in 2
Drop out
n=1
Completed
n=74
Mangia EASL 2010
IL28B-type is associated with increased SVR in non-RVR
patients treated with 24 weeks therapy
Mangia EASL 2010
HCV-2
211*
SVR
151
(72%)
SVR in RVR
108/130
(83%)
SVR in noRVR
43/81
(53%)
CC
79 (37%)
60 (76%)
39/47 (83%)
21/32 (66%)
CT
101 (48%)
72 (71%)
57/67 (85%)
15/34 (44%)
TT
31 (15%)
19 (61%)
12/16 (75%)
7/15 (47%)
HCV-2
77^
SVR^
51/58
(88%)
CC
40 (52%)
51%
21/22 (95%)
1/4 (25%)
CT
29 (38%)
NA
NA
0
TT
8 (10%)
NA
NA
0
Mangia et al.
Sarrazin et al
^ p=0.09 SVR vs NR (follow up information were not for available in all patients)
*in 4 patients IL28B was not determinable
SVR^in RVR
SVR^noRVR
IL 28B: clinical implications in
G2 and G3
G2
RVR (+)
No
role for
IL28B
24 wks
If IL28B CC
G3
RVR (-)
If unfavourable IL28B
48 wks?
DAA?
IL28B with the new drugs
SILEN C-1
BMS 790052 +Peg-IFN
Study design
 Design: Phase IIa multicentre, partially blinded, randomised,
stratified for genotype, multiple-dose trial in France, Italy, Sweden
and UK
TVR
(T mono)
Screening
Peg-IFN + RBV
TVR + Peg-IFN + RBV
(triple therapy)
(T/PR)
Peg-IFN + RBV
PBO + Peg-IFN + RBV
(PR)
Peg-IFN + RBV
2 weeks
Follow up
for  24
weeks
after EOT
24 weeks (T mono arm)
22 weeks (T/PR and PR arms)
TVR 750 mg q8h; Peg-IFN alfa-2a 180g/week; RBV 800mg/day
EOT = end of treatment; PBO = placebo
Median HCV RNA decline from
baseline – G2
Time (Days)
Median change in log10 HCV RNA
0
3
6
9
12
15
0
-1
-2
T mono (n=9)
PR (n=9)
T/PR (n=5)
-3
–3.66
-4
-5
–4.83
–5.51
-6
PROTON
Study Design
HCV GT1
24
12
Week 0
72
48
STOP
N=50
PSI-7977 200 mg QD
Peg-IFN + RBV
Peg-IFN + RBV
N=50
PSI-7977 400 mg QD
Peg-IFN + RBV
Peg-IFN + RBV
Non-RVR Peg-IFN + RBV
STOP
Non-RVR Peg-IFN + RBV
SVR
Follow-Up
Peg-IFN + RBV
N=25
125 treatment-naïve patients with HCV GT1
Planned 12 Week Interim analysis: Nelson, et al. EASL LB poster #1372
HCV GT2/GT3
12
Week 0
N=25
PSI-7977 400 mg QD
Peg-IFN + RBV
SVR12
25 treatment-naïve patients with HCV GT2/3
SVR24
PROTON
HCV GT2/GT3 Antiviral Responses
Week 2
n (evaluable)
HCV RNA <
LOD*
% Response
Lost to follow-up
% Response
(ITT)
Week 4
RVR
Week 12
cEVR/EOT
SVR12
24
24
24
24
21
24
24
24
88%
100%
100%
100%
1
1
1
1
84%
96%
96%
96%
*Roche COBAS TaqMan, LOD 15 IU/mL
PSI-7977 Electron study-GT 1/2/3
Electron study: concordance SVR12 /SVR 24
DEBIO 025 or Alispovir
Rice CM 2011
Alisporivir in GT-2/3: the VITAL study
phase IIb trial of alisporivir in treatment-naïve HCV GT-2 or GT-3 patients
ALV1000
n=83
Alisporivir 600 mg BID
Alisporivir 1000 mg QD*
ALV600R
n=84
Alisporivir 600 mg BID +
RBV
Alisporivir 600 mg QD +
RBV*
ALV800R
n=94
Alisporivir 600 mg BID +
RBV
Alisporivir 800 mg QD +
RBV*
ALV-P
n=39
Alisporivir 600 mg BID +
PegIFN
Alisporivir 600 mg QD +
PegIFN*
PR
n=40
PegIFN/RBV
Week
1
*Patients with HCV RNA ≥25 IU/mL at Week 4 received
alisporivir 600 mg QD + PegIFN/RBV from Week 6 until Week 24
24
Pawlotsky JM, et al. AASLD 2011. Abstract LB-11
26
Alisporivir in GT-2/3: the VITAL study
Patients with undetectable HCV RNA (%)
100
93 95 90 95
85
85
73
80
60
40
37
42
28
20
0
cEVR
RVR
ALV1000
ALV600R
ALV800R
ALV-P
PR
Pawlotsky JM, et al. AASLD 2011. Abstract LB-11
27
Conclusions
• HCV 2 infected represent up to 27% of
chronic pts
• PegIFN/RBV ensure rates of SVR up to
90% even after 12-16 weeks of treatment
• In HCV 2 pts, IL28B has an impact lower
than in HCV 1
• IFN free regimen might became a valuable
alternative to further reduce the Tx
duration
Thank you
Download
Related flashcards

Pediatricians

20 cards

French pediatricians

13 cards

Tourette syndrome

17 cards

British paediatricians

21 cards

Pediatric cancers

13 cards

Create Flashcards